Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study (Dermatology and Therapy, (2024), 14, 12, (3273-3290), 10.1007/s13555-024-01292-z)

The revised version of graphic abstract and Fig. 1 updated here due to error in mislabeling of data on the bar graph. Incorrect version: (Figure presented.) Corrected version: (Figure presented.) Incorrect version: (Figure presented.) Primary and secondary efficacy endpoints. CI confidence interval; DLQI Dermatology Life Quality Index; PSS Psoriasis Symptoms Scale, sPGA static Physicians Global Assessment; Wk week. Non-responder imputation incorporating multiple imputations to handle missing data due to COVID-19 was used; CIs for response rates were based on the Wilson score method Corrected version: (Figure presented.) Primary and secondary efficacy endpoints. CI confidence interval; DLQI Dermatology Life Quality Index; PSS Psoriasis Symptoms Scale, sPGA static Physicians Global Assessment; Wk week. Non-responder imputation incorporating multiple imputations to handle missing data due to COVID-19 was used; CIs for response rates were based on the Wilson score method The original article has been corrected.